Type
|
Public (NASDAQ: ARNA) |
---|---|
Industry | Biotechnology |
Founded | 1997 |
Headquarters | San Diego, California, U.S. |
Key people
|
Jack Lief, cofounder Dominic Behan, co-founder and senior scientist Amit Munshi, CEO Kevin Lind, CFO |
Products | Belviq |
Revenue | US$27,600,000 (FY 2012) |
Operating income
|
US$−57,000,000 (FY 2012) |
Net income
|
US$−85,500,000 (FY 2012) |
Total assets | US$261,000,000 (FY 2012) |
Total equity | US$98,600,000 (FY 2012) |
Website | www |
Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease. In 2016 the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials.
Arena Pharmaceuticals Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. Arena focused on discovering drugs that act on G protein-coupled receptors (GPCRs). The company developed technology it called Constitutively Activated Receptor Technology (CART) that identified drug leads targeting GPCRs and other classes of receptors to. CART was used to identify drug leads able to act as receptor inhibitors to decrease a biological response or act as receptor activators to increase a biological response.
The company has one drug on the market, Belviq (lorcaserin), a weight-loss medication. The U.S. Food and Drug Administration (FDA) approved lorcaserin on June 27, 2012. The company commtitted to a sales force commitment of 200. Lorcaserin is approved for use in adults with a body mass index (BMI) of 30 or greater, which is considered obese, or adults with a BMI of 27 or greater and who have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol. However, sales of Belviq were disappointing. In 2015 the company laid off 80 workers; this was followed in July 2016 by the layoff of another 100 employees (approximately 73% of remaining workforce). In January 2017 Arena announced that it is selling Belviq to its Japanese partner, Eisai Co. Ltd., which will manufacture and market the drug; Arena will draw a royalty on global sales.
The sale completes a pivot in emphasis toward drugs still under development. Drugs in the company's pipeline includes medications designed to treat pain, ulcerative colitis and pulmonary arterial hypertension. As of September 2014, potential products that had not yet been approved by the FDA included Temanogrel (thrombotic diseases), Ralinepag (pulmorary arterial hypertension), APD334 (autoimmune disease), APD371 (pain), and Nelotanserin.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q1 2022 | 2022-05-03 | Future report Set alerts | |
Q4 2021 | 2022-02-23 | -2.39 | -2.39 |
Q3 2021 | 2021-11-04 | -3.21 | -3.21 |
Q2 2021 | 2021-08-05 | -2.40 | -2.40 |
Q1 2021 | 2021-05-05 | -1.98 | -1.98 |
Q4 2020 | 2021-02-23 | -2.10 | -2.10 |
Q3 2020 | 2020-11-09 | 0.00 | 0.00 |
Q2 2020 | 2020-08-05 | -1.61 | -1.61 |
Q1 2020 | 2020-05-07 | -2.00 | -2.00 |
Q4 2019 | 2020-02-26 | -1.76 | -1.76 |
2016-05-10 | Reiterated Rating | Wells Fargo | Hold | |
2016-05-10 | Reiterated Rating | Wells Fargo & Co. | Hold | |
2016-03-02 | Reiterated Rating | Piper Jaffray | Buy | |
2016-03-02 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
2016-03-01 | Reiterated Rating | RBC Capital | Sector Perform | $2.00 to $1.50 |
2016-03-01 | Reiterated Rating | Royal Bank Of Canada | Sector Perform | $2.00 to $1.50 |
2016-01-27 | Reiterated Rating | Needham & Company LLC | Hold | |
2015-11-11 | Reiterated Rating | Needham & Company LLC | Hold | |
2015-11-11 | Lower Price Target | RBC Capital | Sector Perform | $5.00 to $2.00 |
2015-10-30 | Reiterated Rating | Needham & Company LLC | Hold | |
2015-10-28 | Lower Price Target | WallachBeth Capital | Buy | $6.00 to $4.00 |
2015-05-14 | Reiterated Rating | BMO Capital Markets | Market Perform | $9.00 |
2015-05-13 | Reiterated Rating | Needham & Company LLC | Hold | |
2015-05-12 | Lower Price Target | WallachBeth Capital | Buy | $8.00 to $6.00 |
2015-02-02 | Reiterated Rating | Piper Jaffray | Overweight | $7.50 |
2015-01-22 | Initiated Coverage | RBC Capital | Sector Perform | $5.00 |
2015-01-07 | Reiterated Rating | BMO Capital Markets | Positive | |
2014-10-30 | Reiterated Rating | BMO Capital Markets | Market Perform | |
2014-09-04 | Initiated Coverage | Credit Suisse | Underperform | |
2014-09-04 | Initiated Coverage | Credit Suisse Group AG | Underperform | |
2014-08-07 | Reiterated | WallachBeth | Buy | $9 to $8 |
2014-08-07 | Lower Price Target | WallachBeth Capital | Buy | $9.00 to $8.00 |
2014-04-24 | Initiated Coverage | Wells Fargo & Co. | Market Perform | |
2014-04-24 | Initiated Coverage | Wells Fargo | Market Perform | |
2013-11-15 | Initiated | WallachBeth | Buy | $9 |
2013-11-15 | Initiated Coverage | WallachBeth Capital | Buy | $9.00 |
2013-11-11 | Reiterated Rating | Leerink Swann | Outperform | $12.00 |
2013-11-11 | Reiterated Rating | Jefferies Group | Buy | $12.00 |
2013-10-16 | Reiterated Rating | Needham & Company LLC | Hold | |
2013-10-03 | Initiated | Cowen | Market Perform | $4.50 |
2013-10-03 | Initiated Coverage | Cowen and Company | Market Perform | $4.50 |
2013-09-30 | Lower Price Target | Credit Suisse | Underperform | $5.00 to $4.00 |
2010-10-25 | Reiterated | Barclays Capital | Underweight | $3 to $2 |
2010-09-20 | Reiterated | UBS | Neutral | $7 to $2 |
2010-09-17 | Downgrade | Davenport | Buy to Neutral | |
2010-09-14 | Downgrade | Barclays Capital | Equal Weight to Underweight | $4 to $3 |
2010-08-23 | Reiterated | UBS | Neutral | $3.50 to $7 |
2010-07-16 | Downgrade | Rodman & Renshaw | Mkt Perform to Mkt Underperform | $1 |
2010-07-02 | Reiterated | UBS | Buy | $40 to $38 |
2010-02-04 | Upgrade | Rodman & Renshaw | Mkt Underperform to Mkt Perform | |
2009-12-17 | Initiated | Jefferies & Co | Hold | $4 |
2009-09-21 | Downgrade | Leerink Swann | Outperform to Mkt Perform | $6 |
2009-09-18 | Downgrade | Rodman & Renshaw | Mkt Perform to Mkt Underperform | $3 |
2009-09-15 | Downgrade | Rodman & Renshaw | Mkt Outperform to Mkt Perform | |
2009-08-18 | Initiated | JMP Securities | Mkt Perform | |
2009-06-24 | Initiated | Rodman & Renshaw | Mkt Outperform | $9 |
2009-03-16 | Downgrade | Canaccord Adams | Hold to Sell | |
2008-12-10 | Reiterated | UBS | Buy | $8 to $6 |
2016-05-10 | Reiterated Rating | Wells Fargo | Hold | |
2016-05-10 | Reiterated Rating | Wells Fargo & Co. | Hold | |
2016-03-02 | Reiterated Rating | Piper Jaffray | Buy | |
2016-03-02 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
2016-03-01 | Reiterated Rating | RBC Capital | Sector Perform | $2.00 to $1.50 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ARNA 31 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Fund Advisors | 11.23M |
BlackRock Institutional Trust Company, N.A. | 6.24M |
PICTET ASSET MANAGEMENT LTD | 1.09M |
BlackRock Investment Management, LLC | 0.95M |
Marshall Wace North America, L.P. | 0.39M |
BLACKROCK ADVISORS LLC | 0.25M |
BlackRock Group LTD | 0.22M |
TIAA CREF INVESTMENT MANAGEMENT LLC | 0.18M |
TEACHERS ADVISORS INC | 0.11M |
Iguana Healthcare Management, LLC | 100000 |
Numeric Investors LLC | 32000 |
CORNERSTONE CAPITAL MANAGEMENT HOLDINGS LLC. | 21642 |
Dynamic Technology Lab Pte Ltd | 19817 |
Good Harbor Financial, LLC | 16500 |
JANUS CAPITAL MANAGEMENT LLC | 16247 |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
LIEF JACK Chairman, President and CEO | 0.28% (622189) | ARNA / MSTX / |
BEHAN DOMINIC P SVP & Chief Scientific Officer | 0.23% (508000) | ARNA / |
HIXSON HARRY F JR | 0.07% (148405) | ARNA / SQNM / |
BELCHER DONALD D | 0.06% (134257) | ARNA / |
SCHNEIDER PHILLIP M | 0.04% (94257) | ARNA / ASPX / |
BICE SCOTT H | 0.04% (89157) | ARNA / |
White Christine Anna | 0.04% (85529) | ARNA / MEIP / |
WOODS RANDALL E | 0.04% (85257) | ARNA / |
Nova Tina Susan | 0.04% (84257) | ADMP / ARNA / NSTG / VCYT / |
HOFFMAN ROBERT VP, Finance and CFO | 0.03% (58074) | ARNA / CBMX / HRTX / TELK / |
Munshi Amit President and CEO | 0.02% (51875) | ARNA / EPRS / RTGN / |
Audet Craig Michael SVP, Opn & Head Glob Reg Afrs | 0.02% (50000) | ARNA / |
SHANAHAN WILLIAM R JR VP and Chief Medical Officer | 0.02% (50000) | ANTH / ARNA / |
SPECTOR STEVEN W SVP, General Counsel & Sec | 0.01% (19690) | ARNA / |